NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Bristol-Myers Squibb Company BMY
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY18 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$48.2B
▼ 0.2% vs FY2024
Dividend streak
18 yrs
Raised every year since 2008
EPS · FY25
$3.46
Dividend / sh · FY25
$2.49
Payout · FY25
72%
ROE · FY25
40.5%
Net margin · FY25
14.6%
Dividend coverage
1.4×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 48.2B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
15 cents of every revenue dollar became profit this year.
Per share
USD 3.46
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 1.4 times — the rest stayed in the company.
Profitability
40.5%
Return on equity, FY2025
ROE
Operating margin19.4%
Net margin14.6%
Return on assets7.7%
Each USD of equity produced 41 cents of profit this year.
Returned to shareholders
USD 5.0B
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 5.0B
Net buybacksUSD 0.00
Share of profit71.5%
Consecutive raises18 years
USD 5.0B in dividends — 72% of the year's profit went back to shareholders.
Growth
+2.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+1.4%
+2.5%
+11.3%
+6.2%
Net income
+3.7%
+16.2%
+5.6%
EPS, diluted
+5.5%
+14.0%
+4.5%
Dividend / share
+4.4%
+6.2%
+5.3%
+4.5%
Returned to shareholders
−26.4%
−2.1%
+7.4%
+4.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 90.0B
total assets, end of FY2025
Total assetsUSD 90.0B
EquityUSD 18.5B
CashUSD 10.2B
Gross debtUSD 44.8B
Net debtUSD 34.6B
Current ratio1.26×
Net debt stands at 187% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
48.2
48.3
45.0
46.2
46.4
42.5
26.1
22.6
20.8
19.4
16.6
15.9
16.4
17.6
21.2
19.5
18.8
17.7
15.6
Operating income $B
9.3
−8.4
8.4
7.7
8.1
−6.9
5.0
·
·
·
·
·
·
·
·
·
·
·
·
EBITDA $B
13.3
1.2
18.2
18.0
18.8
3.5
6.7
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
2.3
0.6
0.4
1.4
1.1
2.1
1.5
1.0
4.2
1.4
0.4
0.4
0.3
−0.2
1.7
1.6
1.2
1.1
0.5
Net income $B
7.1
−8.9
8.0
6.3
7.0
−9.0
3.4
4.9
1.0
4.5
1.6
2.0
2.6
2.0
3.7
3.1
10.6
5.2
2.2
EPS, diluted $
3.46
−4.41
3.86
2.95
3.12
−3.99
2.01
3.01
0.61
2.65
0.93
1.20
1.54
1.16
2.16
1.79
5.34
2.62
1.09
Dividend / sh $
2.49
2.42
2.31
2.19
2.01
1.84
1.68
1.61
1.57
1.53
1.49
1.45
1.41
1.37
1.33
1.29
1.25
1.24
1.15
Payout %
72
−54
59
73
63
−45
78
53
256
57
158
120
90
117
61
71
23
47
102
ROE %
40.5
−39.1
26.5
18.9
19.0
−20.2
10.5
38.2
7.2
29.3
10.7
13.4
17.8
13.3
23.4
20.3
78.4
42.9
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
65 of 65
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed